Pentosan polysulphate prolongs survival in CJD, study indicates

BMJ 2006; 333 doi: http://dx.doi.org/10.1136/bmj.333.7560.166-d (Published 20 July 2006)
Cite this as: BMJ 2006;333:166.5

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Owen Dyer
  1. London

    An experimental treatment for Creutzfeldt-Jakob disease (CJD) may prolong life but does not seem to halt progressive deterioration of the brain, a study of seven British patients who took the drug has found.

    Pentosan polysulphate, widely prescribed in pill form around the world for urological conditions, is infused directly into the brain of patients with CJD.

    Ian Bone, a Glasgow neurologist, did the study on behalf of the Medical Research Council. Of the seven patients, three had variant CJD (vCJD, contracted from bovine spongiform encephalopathy); two had iatrogenic prion disease from growth hormone; and two had the hereditary form of CJD. All were …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL